GRVY 18.16    Updated: 04-28-2017 $GRVY Last Trade:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
41
GRVY 18.16    Updated: 04-28-2017 $GRVY
Last Trade: 4/28/2017
Last 18.16   
Open 21.50
Previous Close 18.16
Day High / Low 21.50 / 17.53
Year High / Low 39.00 / 3.19
Volume 184,045
Projected Volume 184045 (307%)
# of Trades / Projected 780 / 780
Dividend / Yield - / 0.00%
Abnormal Activity ABNORMAL DAY DOWN
Abnormal Volume ABNORMAL VOLUME
Gap NONE
Candle BEARISH
Volatility Today MEDIUM
Volatility Yesterday MEDIUM
Price Relativity
From 40 Day High 64%
From 80 Day High 50%
From 150 Day High 50%
From 40 Day Low 97%
From 80 Day Low 171%
From 150 Day Low 399%
Pivot Analysis
Price Pivot $ 19.06
Day Resistance 1 $ 20.60
Day Support 1 $ 16.63
Day Resistance 2 $ 23.03
Day Support 2 $ 15.09
Consolidations
Short Term NO
Medium Term YES
Long Term YES
Volume Indicators
20 Day Avg Vol 59,914
Today / 20 Day Avg Vol ABOVE
150 Day Avg Vol 86,137
Today / 150 Day Avg Vol ABOVE
Abnormal Volume ABNORMAL VOLUME
William Volume Accumulation bearish
Volume Price Trend bearish
Momentum Indicators
10 Day Trend bullish
40 Day Trend bearish
100 Day Trend bullish
Stochastics bearish
RSI bearish
MACD bearish
Moving Average Indictors
15 Day Trend bearish
45 Day Trend bearish
100 Day Trend bullish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? ABNORMAL DAY DOWN
Volatility Index Today MEDIUM
Volatility Index Yesterday MEDIUM
10 Day Volatility INCREASING
20 Day Volatility DECREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Sarepta Therapeutics Faces Legal Scrutiny Amid Regulatory Challenges

Updated Category News Views 146

Legal Challenges for Sarepta Therapeutics The situation regarding Sarepta Therapeutics is becoming increasingly complex. Recently, a pending securities class action was initiated due to unsettling news about safety concerns linked to their medication, ELEVIDYS. This product aims to treat Duchenne muscular dystrophy, a severe condition affecting young boys. As the company...

Continue Reading
Enhancing Landscape Operations: LandCare's Partnership with Lytx+™

Updated Category News Views 81

LandCare Enhances Operational Efficiencies with Lytx+ LandCare, a leading commercial landscaping company in the nation, has made significant strides in its operations by adopting the innovative Lytx+™ solution in conjunction with Geotab. This collaboration aims to optimize fleet safety and management, ensuring that LandCare continues to thrive in a competitive...

Continue Reading
Grand Sierra Resort Launches Ambitious $1 Billion Arena Project

Updated Category News Views 292

Grand Sierra Resort Unveils Major Arena Development Grand Sierra Resort (GSR) has officially broken ground on a groundbreaking new arena, marking the first phase of an extensive $1 billion redevelopment project that is set to forever change the landscape of Reno. This ambitious undertaking is the largest private investment in the history of the region, signaling a bright...

Continue Reading
Saba Capital Management Adjusts Holdings in Eaton Vance Trust

Updated Category News Views 74

Saba Capital Management Modifies Its Holdings in Eaton Vance Trust Saba Capital Management, L.P., a significant player in the investment management sector, has recently garnered attention by adjusting its position in the Eaton Vance California Municipal Income Trust (NYSE: CEV). This strategic decision involved the sale of 44,367 shares, accumulating over $484,725 over...

Continue Reading
Key Insights on Treatt Plc's Market Dealing Activities

Updated Category News Views 127

Understanding the Amendment for Treatt Plc The recent amendment related to Treatt Plc has sparked interest in financial circles, especially among shareholders and market analysts. This document outlines public dealing disclosures from an exempt principal trader acting on behalf of a clientele, primarily concerning Treatt Plc, a prominent player in the flavor and fragrance...

Continue Reading